Plasma samples were obtained from 34 bone marrow transplant (BMT) recipients before and after administration of the preparative regimen and tested for their ability to promote and/or support growth of hemopoietic colonies. The ability of plasma samples to promote colony formation on their own was tested on normal nonadherent target cells without addition of exogenous growth factors. The growth-supporting activity was examined in the presence of medium conditioned by phytohemagglutinin-stimulated leukocytes (PHA-LCM) and/or erythropoietin (EPO). A series of kinetic changes was routinely observed. Pretransplant samples rarely gave rise to colonies without addition of exogenous growth factors. Plasma samples obtained after completion of the preparative regimen demonstrated increments of growth-promoting activities for megakaryocyte and granulocyte-macrophage progenitors (CFUMeg and CFU-GM), respectively, that peaked between 7 and 21 d after transplantation. By day 30, activity levels of some patients bad returned to-pretransplant values, whereas in other patients, activities remained elevated. Persisting activity levels were associated with delayed engraftment. In contrast, activities for progenitors committed to erythropoiesis (BFU-E) and pluripotent precursors (CFU-GEMM) were only rarely observed. The activities were independent of febrile episodes. Their growth-promoting influence on CFU-GM could be neutralized completely by anti-granulocyte-macrophage colonystimulating factor (GM-CSF) antibodies. These data suggest that at least some of the observed activities in post-BMT plasma are related to GM-CSF. The growth-supporting activities of pretransplant plasma samples are lower than normal plasma when tested on CFU-Meg and CFU-GM. The growthsupporting activities improved transiently within the first month after BMT. A decline during the second and third month was followed by a gradual return to activity levels that were comparable to normal plasma. 
Introduction
Human recombinant hemopoietic growth factors are now available and have shown effectiveness in cell culture (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Preclinical and clinical studies have also demonstrated their ability to increase the level of peripheral blood cells in vivo (1 1-15) . A well-timed administration of these growth factors to bone marrow transplant (BMT)' recipients may provide the opportunity to improve the speed and quality of bone marrow recovery after BMT (16) . In a previous study (17) now confirmed (18) , we were able to demonstrate that plasma samples collected from 11 BMT recipients contained activities that promoted growth of progenitors committed to megakaryocytopoiesis (CFLJ-Meg) and granulocyte-macrophage production (CFU-GM). Some of these samples also facilitated the development of erythroid bursts, while multilineage colonies were not observed. Operationally, the described activities supported and promoted the growth of hemopoietic progenitors replacing the requirement for an additional source of exogenous growth factors completely or at least partially. This contrasts with the finding that normal plasma samples give rise to hemopoietic colonies only if a source of exogenous growth factors is added to the cultures (19) . It is the purpose ofthis investigation to describe growth-supporting and growth-promoting, growth factor-like activities in the plasma of BMT recipients collected before and serially after BMT. In addition, attempts are made to determine whether or not a correlation exists between the kinetic behavior of these activities and engraftment. 1 . Abbreviations used in this paper: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BFU-E, progenitor committed to erythropoiesis; BMT, bone marrow transplantation; CFU-GEMM, pluripotent precursor; CFU-GM, progenitor committed to granulocyte-macrophage production; CFU-Meg, progenitor committed to megakaryocytopoiesis; CML, chronic myeloid leukemia; EPO, erythropoietin; GM-CSF, granulocyte-macrophage colony-stimulating factor, GvHD, graft vs. host disease; IL3, Interleukin 3 2ME, 2-mercaptoethanol; PHA-LCM, medium conditioned by PHA-stimulated leukocytes; rg, recombinant gibbon; rh, recombinant human; WRS,
Methods
Patients. 34 consenting patients that received marrow grafts from HLA-identical sibling donors were studied prospectively. These included eight individuals with acute myeloid leukemia (AML), seven with acute lymphoblastic leukemia (ALL), 14 with chronic myeloid leukemia (CML), one with aplastic anemia, three with multiple myeloma, and with malignant lymphoma. In addition, plasma samples of 27 additional patients were examined who had at least survived yr after BMT. All recipients were prepared according to previously published protocols (20) . Graft versus host disease (GvHD) prophylaxis included administration of four doses of methotrexate followed by prednisone 40 mg/M2 perd from day 10 ( 17, 19, 22) .
In some experiments, nonadherent mononuclear target cells were further depleted of T lymphocytes using a double rosetting procedure with 2-aminoethylisothio-uronium bromide hydrobromide treated sheep red blood cells (23) .
Bioassayfor hemopoietic growthfactors in human plasma. Nonad (19, 22) . Colonies were scored after 14 d ofculture in a humidified atmosphere containing 5% CO2 using previously described criteria (19, 22, 23, 25 Neutralization studies with anti-GM-CSF and anti-IL-3. Recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) (1, 26) and recombinant gibbon (rg 9, 26) IL-3 were obtained as supernantants of chinese hamster ovary cells and monkey COS-I cells which had been transfected with the respective genes. Both growth factors as well as affinity-purified antibody preparations (9) raised in sheep against rh GM-CSF and in rabbits against rg IL-3 were a generous gift of Dr. S. C. Clark (Genetics Institute, Boston, MA).
150 ,d of each plasma sample obtained from BMT recipients were incubated in Eppendorff tubes for 1 h at 370C using the antibody preparations in dilutions from 1:50 to 1:5,000 and kept overnight at 4VC. The resulting immune complexes were removed from the plasma by centrifugation at 1,500 g after a 2-h incubation at 4VC with protein G-bearing Omnisorb cells (Calbiochem, Terochem Laboratories, Mississauga, Ontario) (27) . The plasma specimens were tested without further addition of growth factors at a final concentration of 30% using 5 X 103 E rosette-depleted (23), nonadherent normal bone marrow cells plated in flat-bottomed microtiter plates (Nunclon, Gibco Canada, Burlington, Ontario), in a volume of 0.1 ml containing methylcellulose, 2ME, and Iscove's modified Dulbecco's medium as described above. The target cell population was also plated with rh GM-CSF and rg IL-3 as well as growth factor preparations that had been preincubated with anti-GM-CSF and anti-IL-3.
Statistical methods. The activity levels used in the statistical analysis were calculated as a percentage ofthe maximal colony formation of normal controls above the background colony formation.
For the purpose of this study, time to engraftment was defined for each lineage as the time elapsing between the transplant and the day when > 50,000 platelets, > 50,000 reticulocytes, or > 1,500 granulocytes/mm3 of peripheral blood were recorded and subsequently sustained without transfusions. Platelet counts on the day ofor on the day after platelet transfusions were not considered for this study. None of the patients received granulocyte transfusions. Each patient was evaluated for the presence of GvHD following established criteria (28) . The Wilcoxon rank-sum test (WRS) was used for comparisons between groups of measurements (29) . The Wilcoxon signed rank test (WSR) was used to test the location of the mean of a population of measurements (29) .
Results
All samples were tested on normal nonadherent target cells for growth-promoting activities in the absence of other exogenous sources of growth factors. In addition, specimens were examined for their ability to support growth of hemopoietic progenitors in the presence of PHA-LCM. The majority of target cells did not form colonies when plated with normal human plasma in the absence of additional growth factors.
Activities for CFU-Meg
Testing ofplasma samples without PHA-LCM. Plasma samples collected from BMT recipients before transplantation usually contained activities that promoted growth of a small number of megakaryocyte colonies in the absence of PHA-LCM (Fig. 1) . The activity levels increased by the day of the transplant (day 0), determined before infusion of the bone marrow. Maximal levels were reached between days 7 and 26. These varied considerably from patient to patient. Plasma of some patients promoted growth of more megakaryocyte colonies than normal human plasma and PHA-LCM, while samples obtained from other patients resulted in suboptimal colony formation.
The (Fig. 2 A) was observed in 15 patients (four ALL, four AML, four CML, two multiple myeloma, one malignant lymphoma). The activity levels in 13 patients (two ALL, three AML, seven CML, one multiple myeloma) were sustained beyond day 30 (Fig. 2 B) . The only patient in this study transplanted for aplastic anemia showed a different activity profile (Fig. 2 C) . The pretransplant plasma promoted megakaryocyte colony growth better than controls plated with normal plasma and PHA-LCM. The activity declined gradually and by day 60 the plasma behaved like normal plasma.
The data points collected for five patients were not sufficient to assign them to a specific activity profile. All available plasma samples of one of these five patients were void of stimulatory activity (Fig. 2 D) . This Testing ofplasma samples with PHA-LCM. The plasma samples were also evaluated in the presence of PHA-LCM (Table I ). The frequency of colonies observed with plasma obtained before administration ofthe preparative regimen was significantly lower than with normal plasma. The plating efficiency increased with plasma obtained between days 0 and 30 of the BMT. The growth support exerted by plasma collected from BMT recipients between days 7 and 30 approximated the activity level usually observed with normal plasma. Plasma samples obtained between days 50 and 100 after BMT supported megakaryocyte colony growth in the presence of PHA-LCM to a significantly lesser degree than normal plasma: this was significant at the 0.05 level for days 50 and 100 (WSR, P = 0.001 and P = 0.030, respectively) and significant at the 0.10 level for day 60 (WSR, P = 0.059). Specimens studied 5-48 mo after BMT provided nearly normal growth support (Table I) .
Activities for CFU-GM Plasma samples obtained from BMT recipients before transplantation occasionally promoted growth ofa small number of granulocyte-macrophage colonies in the absence of PHA-LCM (Fig. 1) . Growth-promoting activities were routinely observed 7-14 d after BMT. The colony frequency approximated 50% of controls grown with normal plasma and PHA-LCM. The variability of activity profiles for individual patients was less compared to activities for CFU-Meg.
The frequency of granulocyte-macrophage colonies observed in the presence of PHA-LCM and plasma collected from BMT the growth of fewer granulocyte-macrophage colonies than normal plasma when tested with PHA-LCM. Days 40 and 50 were significantly different from normal at the 0.05 level (WSR, P = 0.003 and 0.030). The activity on day 100 differed at the 0.10 level (WSR, P = 0.093). A return to normal supporting activities was observed 5 mo after BMT (Table I) .
Activities for BFU-E and CFU-GEMM Erythroid bursts and multilineage colonies with erythroid components were only occasionally observed when normal nonadherent target cells were plated with plasma in the absence of PHA-LCM and exogenous EPO. Addition of EPO to the cultures did not improve the plating efficiency significantly. The use of PHA-LCM without exogenous EPO resulted in the formation of some erythroid bursts and multilineage colonies when plasma samples obtained from recipients early after BMT were examined. The plating efficiency of BFU-E and CFU-GEMM, however, did not exceed 30% ofthe established maximal controls. This observation suggests that plasma samples collected within the first 4-6 wk after BMT contain some EPO. The plating efficiency was further improved when EPO and PHA-LCM was added to the cultures.
Plasma samples collected around day 50 again demonstrated a deficiency in supporting growth of BFU-E and CFU-GEMM under otherwise maximally stimulated culture conditions. Long-term observation indicated that the growth-supporting activity improved in plasma samples collected 5 mo or later after BMT (Table I) .
Neutralization ofgrowth-promoting activities for CFU-GM in post-BMT plasma by anti-GM-CSF antibodies Post-BMT plasma samples were exposed to anti-GM-CSF and anti-IL-3 antibodies to determine whether or not the activities identified in the biological assay system were related to known hemopoietic growth factors. The E rosette-depleted, nonadherent target cells did not form colonies in the absence of growth factors, but gave rise to granulocyte-macrophage colonies when either rh GM-CSF or rg IL-3 were added (Table II) . Colony formation under the influence of rh GM-CSF and rg IL-3 was abrogated by preincubation with respective antibody preparations. Similarly, the growth promoting activity for CFU-GM identified by bioassay in six tested plasma samples was completely neutralized after preincubation with anti-GM-CSF. The neutralization was concentration dependent (Table II) . In contrast, similar studies with anti-IL-3 on two plasma samples did not result in a reduction of the growth promoting activity.
The frequency of megakaryocyte colonies per microwell was too low to permit definitive conclusions about the influence of anti-GM-CSF and anti-IL-3 on plasma activities that promote the growth of megakaryocyte colonies.
Clinical correlation
Influence of plasma activities on time to engraftment. We compared the growth-promoting activities in plasma samples before and after BMT with time to recovery of single lineage peripheral blood counts. The distributions ofthe plasma activities at each time were determined. The times to recovery of platelets, granulocytes, and reticulocytes were compared for patients with activities above and below the median. Only the day 30 post-BMT activity level for megakaryocyte precursors was significantly related to the time to engraftment as determined for platelets. Patients with activity levels less than the median tended to engraft faster than patients with activity levels greater than the median (WRS, P = 0.017). A similar trend was observed for stimulating activities for granulocytemacrophage precursors. Higher activities than the median, around day 30, were associated with slower engraftment as (14) 0 Anti-GM-CSF 14 ND 5 0 0 BMT 210 (7) 0 Anti-GM-CSF determined for granulocytes, although the difference was not significant at the 0.05 level (WRS, P = 0.059). Activities higher than the median for BFU-E observed at day 21 after BMT were also consistent with a slower return of reticulocytes (WRS, P = 0.012). The activity levels measured at all other times posttransplant were not significantly related to time to engraftment for any of the three lineages.
Influence offebrile episodes on colony-stimulating activities in post-BMT plasma. The observed growth-promoting activities in post-BMT plasma may be related to the release of endotoxin during febrile episodes. We therefore excluded from the analysis 19 samples that were collected during a febrile episode or within 4 d of defervescence. The activity profiles of this subgroup of 196 samples were indistinguishable from those of all 215 samples depicted in Fig. 1 . In addition, 19 patients remained completely afebrile during their post BMT course. Separate assessment of their 111 plasma samples also resulted in similar activity profiles.
Influence of GvHD. Based on our previous study (30), GvHD has a major influence on engraftment. We therefore determined whether or not the observed activity profiles for CFU-Meg differed for patients with and without GvHD. As previously observed, patients with GvHD in this study also engrafted slower (25 vs. 35 d: WRS, P = 0.039). Examination for the activity profiles yielded some possible differences. Patients with GvHD appeared to have higher peak activities than patients without GvHD, and patients with GvHD had a tendency to sustain activities longer. However, these differences were not statistically significant at the 0.05 level.
Discussion
Plasma samples collected from BMT recipients after administration of their respective ablative pretransplant therapy routinely promoted growth of megakaryocyte and granulocytemacrophage colonies in the absence of any additional source of hemopoietic growth factors. The growth-promoting activities usually peaked 7-21 d after BMT. The return time to pretransplant levels varied considerably from patient to patient. The duration correlated with time to engraftment. Patients that demonstrated growth-promoting activities over prolonged time periods tended to engraft at a slower rate. The growth-promoting activities were observed independent of febrile episodes and documented infections. This information makes it unlikely that growth-promoting activities in post-BMT plasma simply reflect the influence of endotoxin.
The neutralization studies using antibodies against GM-CSF and IL-3 provided evidence for the view that at least the stimulatory activities for CFU-GM in the six tested plasma samples are consistent with GM-CSF. The simultaneous presence of GM-CSF and EPO may account for the formation of occasional erythroid bursts and multilineage colonies. GM-CSF in these plasma samples may also give rise to some megakaryocyte colonies. However, the magnitude of the stimulatory effect for CFU-Meg may suggest the presence of a specific megakaryocyte colony-stimulating activity, since GM-CSF alone only promotes megakaryocyte colony formation by a small subpopulation of available CFU-Meg (26) . In addition, the stimulatory activity for CFU-Meg in post-BMT plasma is likely not related to IL-3. Our studies including the neutralization attempts with anti-IL-3 provided little evidence for the release of IL-3.
These initial investigations suggest that hemopoietic growth factors may play a role in the engraftment process. The persistance of growth-promoting activities in the plasma of BMT recipients with delayed engraftment bears resemblance to similar observations in severe aplastic anemia (17) and other cell deficiencies (31) (32) (33) . Besides cellular defects, one may have to consider deficiencies of factors that interact with earlier pluripotent progenitors such as IL-1 (34) and IL-6 (35) . Alternatively, some of the effects may reflect inhibitory mechanisms as previously suggested (36) . Future studies are necessary to determine the full spectrum of growth factors, their cellular sources of host and/or donor origin, and mechanisms that are involved in their synthesis and release in relationship to BMT. This information on the endogenous production of growth factors and an understanding of the described growth-supporting plasma activities and their fluctuation after BMT may provide further insight into the engraftment process, and may explain mechanisms of delayed engraftment and graft failure. The data will aid in the design and interpretation of clinical trials using human recombinant hemopoietic growth factors in BMT.
